Neuroblastoma screening
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Zahir Ali Shaikh, MD[2]Haytham Allaham, M.D. [3]
Overview
There is insufficient evidence to recommend the routine screening for neuroblastoma as it has no mortality benefits.
Screening
- There is insufficient evidence to recommend the routine screening for neuroblastoma by measuring the vanillylmandelic acid and homovanillic acid at 6 months or 1 year or age, as it does not have the mortality benefits.[1][2][3][4]
References
- ↑ Recommendations. US Preventive Services Task Force(2015) http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=neuroblastoma Accessed on October, 5 2015
- ↑ William G. Woods, Ru-Nie Gao, Jonathan J. Shuster, Leslie L. Robison, Mark Bernstein, Sheila Weitzman, Greta Bunin, Isra Levy, Josee Brossard, Geoffrey Dougherty, Mendel Tuchman & Bernard Lemieux (2002). “Screening of infants and mortality due to neuroblastoma”. The New England journal of medicine. 346 (14): 1041–1046. doi:10.1056/NEJMoa012387. PMID 11932470. Unknown parameter
|month=ignored (help) - ↑ Freimut H. Schilling, Claudia Spix, Frank Berthold, Rudolf Erttmann, Natalja Fehse, Barbara Hero, Gisela Klein, Johannes Sander, Kerstin Schwarz, Joern Treuner, Ulrich Zorn & Joerg Michaelis (2002). “Neuroblastoma screening at one year of age”. The New England journal of medicine. 346 (14): 1047–1053. doi:10.1056/NEJMoa012277. PMID 11932471. Unknown parameter
|month=ignored (help) - ↑ “Neuroblastoma Screening (PDQ(R)): Health Professional Version”. 2002. PMID 26389460.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH